Pentadecapeptide
Also known as: BPC-157 Full Sequence, Stable Gastric Pentadecapeptide
Key Facts: Pentadecapeptide
- Category
- Healing
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - Same research base as BPC-157. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
- Administration
- Subcutaneous injection
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Duration
- 4-12 weeks typical
Mechanism of Action
Like BPC-157, the pentadecapeptide modulates the nitric oxide system, promotes angiogenesis, and accelerates tissue healing. It interacts with multiple growth factor systems and has cytoprotective effects on various tissues.
Research Summary
Research largely overlaps with BPC-157 studies, showing tissue healing, gastroprotection, and recovery enhancement. The pentadecapeptide terminology is sometimes used interchangeably with BPC-157 in scientific literature.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses similar to BPC-157 protocols
Doses from Studies
250-500 mcg twice daily
Duration
4-12 weeks typical
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Morning and evening (or near injury site timing)
1-2 times daily, consistent timing
Food Recommendation
With or without food
Why This Timing?
BPC-157 has systemic healing effects. Split dosing maintains stable levels. Can be timed around activity for injury healing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●See BPC-157 (same compound)
- ●Generally well-tolerated
- ●Nausea
- ●Dizziness
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
References
- https://pubmed.ncbi.nlm.nih.gov/29898090/
- https://pubmed.ncbi.nlm.nih.gov/30915550/
- https://pubmed.ncbi.nlm.nih.gov/27847280/
Research This Peptide Further
Frequently Asked Questions
What does Pentadecapeptide do?
The full 15-amino acid sequence that includes BPC-157. While BPC-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice.
How does Pentadecapeptide work?
Like BPC-157, the pentadecapeptide modulates the nitric oxide system, promotes angiogenesis, and accelerates tissue healing. It interacts with multiple growth factor systems and has cytoprotective effects on various tissues.
Is Pentadecapeptide FDA approved?
No, Pentadecapeptide is not currently FDA approved. Current status: Preclinical - Same research base as BPC-157. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
What are the side effects of Pentadecapeptide?
Reported side effects include: See BPC-157 (same compound), Generally well-tolerated, Nausea, Dizziness, May trigger histamine release - use caution with MCAS or histamine sensitivity. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Pentadecapeptide?
Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Pentadecapeptide or used in similar applications.
BPC-157
PreclinicalA synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
HealingTB-500
PreclinicalA synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.
HealingThymosin Beta-4
Clinical TrialsThe full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues, TB-4 has a shorter half-life (~2 hours) compared to its synthetic fragment TB-500 (~2-4 days). Often mislabeled as 'TB-500' by vendors in premixed products.
HealingZiconotide
FDAA synthetic cone snail venom peptide for severe chronic pain. The first intrathecal non-opioid analgesic FDA approved.
HealingWolverine Stack
PreclinicalThe most popular healing peptide combination, combining BPC-157 (10mg) and TB-500 (10mg). Named after the Marvel character's regenerative abilities. Used for accelerated injury recovery, joint support, and tissue repair.
Peptide BlendGlow Protocol
PreclinicalA multi-peptide skin rejuvenation blend combining BPC-157 (5mg), TB-500 (10mg), and GHK-Cu (27mg). Designed for anti-aging, skin health, and tissue repair with a focus on collagen production and cellular regeneration.
Peptide BlendWant updates on Pentadecapeptide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.